Sabrina Ronen, PhD
Professor
Radiology
School of Medicine

She then trained as a postdoctoral fellow at the Institut Curie in Paris, France, and started her academic career at the Institute of Cancer Research in London, England.

Dr. Ronen’s Laboratory focuses on developing and mechanistically validating robust non-invasive translatable magnetic resonance (MR)–based biomarkers that can be used to monitor oncogenic transformation and response to therapy. Dr. Ronen has ongoing research projects on monitoring PI3K signaling, detecting the mutational status of isocitrate dehydrogenase, probing the metabolism of brain tumors, and determining the metabolomic profile of pancreatic cancer.

Expertise: Magnetic resonance spectroscopy (MRS), spectroscopic imaging (MRSI), imaging (MRI), metabolism, cancer, bioengineering

Specialty: Preclinical cancer models

Professional Interests: Magnetic resonance, spectroscopy, imaging, cancer, metabolism, cell signaling, biomarkers

Education and Training:

• Bachelor of Science: Hebrew University, Jerusalem, Israel - Cum Laude, Chemistry and Biochemistry
• Masters of Science: San Jose State University, San Jose - Chemistry
• Doctor of Philosophy: Weizmann Institute of Science, Rehovot, Israel - Chemical Physics
• Postdoctoral Fellowship: Institut Curie, Paris, France - Imaging
• Postdoctoral Fellowship: Harefield Hospital, London, England - Imaging

• Deuterium Metabolic Imaging Reports on TERT Expression and Early Response to Therapy in Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Batsios G, Taglang C, Tran M, Stevers N, Barger C, Gillespie AM, Ronen SM, Costello JF, Viswanath P
• Deuterium magnetic resonance spectroscopy enables noninvasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.
  Neuro-oncology 2022 Taglang C, Batsios G, Mukherjee J, Tran M, Gillespie AM, Hong D, Ronen SM, Artee Luchman H, Pieper RO, Viswanath P
• Acquisition and quantification pipeline for in vivo hyperpolarized 13 C MR spectroscopy.
  Magnetic resonance in medicine 2021 Hong D, Batsios G, Viswanath P, Gillespie AM, Vaidya M, Larson PEZ, Ronen SM
• Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.
  Neuro-oncology 2021 Viswanath P, Batsios G, Ayyappan V, Taglang C, Gillespie AM, Larson PEZ, Luchman HA, Costello JF, Pieper RO, Ronen SM
• Imaging 6-Phosphogluconolactonase Activity in Brain Tumors In Vivo Using Hyperpolarized δ-[1-13C]gluconolactone.
  Frontiers in oncology 2021 Batsios G, Taglang C, Cao P, Gillespie AM, Najac C, Subramani E, Wilson DM, Flavell RR, Larson PEZ, Ronen SM, Viswanath P
• Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma.
  Metabolites 2021 Radoul M, Hong D, Gillespie AM, Najac C, Viswanath P, Pieper RO, Costello JF, Luchman HA, Ronen SM
• Non-invasive assessment of telomere maintenance mechanisms in brain tumors.
  Nature communications 2021 Viswanath P, Batsios G, Mukherjee J, Gillespie AM, Larson PEZ, Luchman HA, Phillips JJ, Costello JF, Pieper RO, Ronen SM
• Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
  Cancer research 2020 Subramani E, Radoul M, Najac C, Batsios G, Molloy AR, Hong D, Gillespie AM, Santos RD, Viswanath P, Costello JF, Pieper RO, Ronen SM
• Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma.
  Neuro-oncology advances 2020 Jones LE, Hilz S, Grimmer MR, Mazor T, Najac C, Mukherjee J, McKinney A, Chow T, Pieper RO, Ronen SM, Chang SM, Phillips JJ, Costello JF
• MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
  Theranostics 2020 Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M, Gillespie AM, Pieper RO, Ronen SM
• In vivo detection of γ-glutamyl-transferase up-regulation in glioma using hyperpolarized γ-glutamyl-[1-13C]glycine.
  Scientific reports 2020 Batsios G, Najac C, Cao P, Viswanath P, Subramani E, Saito Y, Gillespie AM, Yoshihara HAI, Larson P, Sando S, Ronen SM
• First hyperpolarized [2-13C]pyruvate MR studies of human brain metabolism.
  Journal of magnetic resonance (San Diego, Calif. : 1997) 2019 Chung BT, Chen HY, Gordon J, Mammoli D, Sriram R, Autry AW, Le Page LM, Chaumeil MM, Shin P, Slater J, Tan CT, Suszczynski C, Chang S, Li Y, Bok RA, Ronen SM, Larson PEZ, Kurhanewicz J, Vigneron DB
• PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
  Scientific reports 2019 Batsios G, Viswanath P, Subramani E, Najac C, Gillespie AM, Santos RD, Molloy AR, Pieper RO, Ronen SM
• In vivo investigation of hyperpolarized [1,3-13C2]acetoacetate as a metabolic probe in normal brain and in glioma.
  Scientific reports 2019 Najac C, Radoul M, Le Page LM, Batsios G, Subramani E, Viswanath P, Gillespie AM, Ronen SM
• HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI.
  NMR in biomedicine 2018 Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM
• Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology.
  Neoplasia (New York, N.Y.) 2018 Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, Gallagher FA, Keshari KR, Kjaer A, Laustsen C, Mankoff DA, Merritt ME, Nelson SJ, Pauly JM, Lee P, Ronen S, …
• Late-stage deuteration of 13C-enriched substrates for T1 prolongation in hyperpolarized 13C MRI.
  Chemical communications (Cambridge, England) 2018 Taglang C, Korenchan DE, von Morze C, Yu J, Najac C, Wang S, Blecha JE, Subramaniam S, Bok R, VanBrocklin HF, Vigneron DB, Ronen SM, Sriram R, Kurhanewicz J, Wilson DM, Flavell RR
• Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.
  Cancer & metabolism 2018 Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM
• 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.
  Cancer research 2018 Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper RO, Phillips JJ, Ronen SM
• Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.
  Proceedings of the National Academy of Sciences of the United States of America 2017 Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, …
• Hyperpolarized 13C MR metabolic imaging can detect neuroinflammation in vivo in a multiple sclerosis murine model.
  Proceedings of the National Academy of Sciences of the United States of America 2017 Guglielmetti C, Najac C, Didonna A, Van der Linden A, Ronen SM, Chaumeil MM
• Autophagy-Dependent Shuttling of TBC1D5 Controls Plasma Membrane Translocation of GLUT1 and Glucose Uptake.
  Molecular cell 2017 Roy S, Leidal AM, Ye J, Ronen SM, Debnath J
• Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma.
  Scientific reports 2017 Jalbert LE, Elkhaled A, Phillips JJ, Neill E, Williams A, Crane JC, Olson MP, Molinaro AM, Berger MS, Kurhanewicz J, Ronen SM, Chang SM, Nelson SJ
• GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.
  JCI insight 2017 Kuang R, Jahangiri A, Mascharak S, Nguyen A, Chandra A, Flanigan PM, Yagnik G, Wagner JR, De Lay M, Carrera D, Castro BA, Hayes J, Sidorov M, Garcia JLI, Eriksson P, Ronen S, Phillips J, Molinaro A, …
• Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.
  Cancer research 2016 Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JF, Ronen SM, Pieper RO
• MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy.
  Topics in magnetic resonance imaging : TMRI 2016 Najac C, Ronen SM
• Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine.
  Scientific reports 2016 Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM
• Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
  Molecular cancer research : MCR 2016 Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper RO
• Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
  NeuroImage. Clinical 2016 Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG, Ronen SM
• Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.
  Oncotarget 2016 Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov A, Hong C, Eriksson P, Costello JF, Pieper RO, Ronen SM
• Imaging Renal Urea Handling in Rats at Millimeter Resolution using Hyperpolarized Magnetic Resonance Relaxometry.
  Tomography (Ann Arbor, Mich.) 2016 Reed GD, von Morze C, Verkman AS, Koelsch BL, Chaumeil MM, Lustig M, Ronen SM, Bok RA, Sands JM, Larson PE, Wang ZJ, Larsen JH, Kurhanewicz J, Vigneron DB
• Accelerated high-bandwidth MR spectroscopic imaging using compressed sensing.
  Magnetic resonance in medicine 2016 Cao P, Shin PJ, Park I, Najac C, Marco-Rius I, Vigneron DB, Nelson SJ, Ronen SM, Larson PE
• Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells.
  Frontiers in oncology 2016 Viswanath P, Chaumeil MM, Ronen SM
• MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
  Molecular cancer therapeutics 2016 Radoul M, Chaumeil MM, Eriksson P, Wang AS, Phillips JJ, Ronen SM
• 1 H-13 C independently tuned radiofrequency surface coil applied for in vivo hyperpolarized MRI.
  Magnetic resonance in medicine 2015 Cao P, Zhang X, Park I, Najac C, Nelson SJ, Ronen S, Larson PE
• Magnetic Resonance (MR) Metabolic Imaging in Glioma.
  Brain pathology (Zurich, Switzerland) 2015 Chaumeil MM, Lupo JM, Ronen SM
• Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1.
  Molecular & cellular oncology 2015 Viswanath P, Ronen SM
• Studies of Metabolism Using (13)C MRS of Hyperpolarized Probes.
  Methods in enzymology 2015 Chaumeil MM, Najac C, Ronen SM
• IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.
  Cancer research 2015 Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, Blough M, Luchman HA, Weiss S, Cairncross JG, Phillips JJ, Pieper RO, Ronen SM
• Metabolic reprogramming in mutant IDH1 glioma cells.
  PloS one 2015 Izquierdo-Garcia JL, Viswanath P, Eriksson P, Chaumeil MM, Pieper RO, Phillips JJ, Ronen SM
• Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells.
  Cancer research 2014 Park I, Mukherjee J, Ito M, Chaumeil MM, Jalbert LE, Gaensler K, Ronen SM, Nelson SJ, Pieper RO
• Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
  PloS one 2014 Izquierdo-Garcia JL, Cai LM, Chaumeil MM, Eriksson P, Robinson AE, Pieper RO, Phillips JJ, Ronen SM
• Rapid in vivo apparent diffusion coefficient mapping of hyperpolarized (13) C metabolites.
  Magnetic resonance in medicine 2014 Koelsch BL, Reed GD, Keshari KR, Chaumeil MM, Bok R, Ronen SM, Vigneron DB, Kurhanewicz J, Larson PEZ
• HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer.
  NMR in biomedicine 2014 Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM
• Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
  Cancer research 2014 Chaumeil MM, Larson PE, Woods SM, Cai L, Eriksson P, Robinson AE, Lupo JM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, Ronen SM
• Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer.
  Cell 2014 Cunningham JT, Moreno MV, Lodi A, Ronen SM, Ruggero D
• MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.
  NMR in biomedicine 2014 Lodi A, Woods SM, Ronen SM
• Lactate dehydrogenase A silencing in IDH mutant gliomas.
  Neuro-oncology 2013 Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, Pieper RO, Ronen SM, Weiss S, Luchman HA, Cairncross JG
• Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage.
  PloS one 2013 Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper RO
• HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells.
  PloS one 2013 Ward CS, Eriksson P, Izquierdo-Garcia JL, Brandes AH, Ronen SM
• Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma.
  PloS one 2013 Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO
• Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK
• Non-invasive in vivo assessment of IDH1 mutational status in glioma.
  Nature communications 2013 Chaumeil MM, Larson PE, Yoshihara HA, Danforth OM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, Ronen SM
• Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells.
  NMR in biomedicine 2012 Lodi A, Woods SM, Ronen SM
• Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging.
  Magnetic resonance in medicine 2012 Park I, Hu S, Bok R, Ozawa T, Ito M, Mukherjee J, Phillips JJ, James CD, Pieper RO, Ronen SM, Vigneron DB, Nelson SJ
• Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla.
  Neuro-oncology 2012 Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM
• Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.
  Neuro-oncology 2011 Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM
• Vascular patterning and permeability in prostate cancer models with differing osteogenic properties.
  NMR in biomedicine 2011 Dafni H, Burghardt AJ, Majumdar S, Navone NM, Ronen SM
• Choline metabolism in malignant transformation.
  Nature reviews. Cancer 2011 Glunde K, Bhujwalla ZM, Ronen SM
• Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.
  PloS one 2011 Lodi A, Ronen SM
• Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells.
  NMR in biomedicine 2011 Su JS, Woods SM, Ronen SM
• Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma.
  NeuroImage 2011 Chaumeil MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, Ronen SM
• Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.
  Journal of magnetic resonance imaging : JMRI 2011 Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, Ronen SM, Nelson SJ
• Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation.
  Molecular biology of the cell 2010 Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, Debnath J
• 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.
  Breast cancer research : BCR 2010 Brandes AH, Ward CS, Ronen SM
• Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor.
  Cancer research 2010 Dafni H, Larson PE, Hu S, Yoshihara HA, Ward CS, Venkatesh HS, Wang C, Zhang X, Vigneron DB, Ronen SM
• Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
  Neuro-oncology 2010 Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK
• Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.
  Cancer research 2010 Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM
• Dynamic nuclear polarization in metabolic imaging of metastasis: common sense, hypersense and compressed sensing.
  Cancer biomarkers : section A of Disease markers 2010 Dafni H, Ronen SM
• Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation.
  Magnetic resonance in medicine 2008 Dafni H, Kim SJ, Bankson JA, Sankaranarayanapillai M, Ronen SM
• Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine.
  Molecular cancer therapeutics 2008 Ross J, Najjar AM, Sankaranarayanapillai M, Tong WP, Kaluarachchi K, Ronen SM
• Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic resonance spectroscopy method.
  Molecular imaging 2008 Sankaranarayanapillai M, Tong WP, Yuan Q, Bankson JA, Dafni H, Bornmann WG, Soghomonyan S, Pal A, Ramirez MS, Webb D, Kaluarachchi K, Gelovani JG, Ronen SM
• Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy.
  Molecular cancer therapeutics 2006 Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen SM
• Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells.
  Molecular cancer therapeutics 2006 Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, Workman P, Leach MO, Ronen SM
• Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition.
  Cancer research 2005 Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM
• Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
  Journal of the National Cancer Institute 2003 Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM
• Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells.
  British journal of cancer 2001 Ronen SM, Jackson LE, Beloueche M, Leach MO
• Imaging biochemistry: applications to breast cancer.
  Breast cancer research : BCR 2000 Ronen SM, Leach MO
• Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000 Smith TA, Maisey NR, Titley JC, Jackson LE, Leach MO, Ronen SM
• Applications of magnetic resonance in model systems: cancer therapeutics.
  Neoplasia (New York, N.Y.) 2000 Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, Swartz HM
• Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis.
  British journal of cancer 1999 Ronen SM, DiStefano F, McCoy CL, Robertson D, Smith TA, Al-Saffar NM, Titley J, Cunningham DC, Griffiths JR, Leach MO, Clarke PA
• Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment.
  NMR in biomedicine 1998 Leach MO, Verrill M, Glaholm J, Smith TA, Collins DJ, Payne GS, Sharp JC, Ronen SM, McCready VR, Powles TJ, Smith IE
• Comparative NMR study of a differentiated rat hepatoma and its dedifferentiated subclone cultured as spheroids and as implanted tumors.
  NMR in biomedicine 1994 Ronen SM, Volk A, Mispelter J
• The application of 13C NMR to the characterization of phospholipid metabolism in cells.
  Magnetic resonance in medicine 1992 Ronen SM, Degani H
• Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake.
  Biochimica et biophysica acta 1992 Ronen SM, Rushkin E, Degani H
• Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake.
  Biochimica et biophysica acta 1991 Ronen SM, Rushkin E, Degani H
• NMR studies of the lipid metabolism of T47D human breast cancer spheroids.
  FEBS letters 1990 Ronen SM, Stier A, Degani H
• Studies of the metabolism of human breast cancer spheroids by NMR.
  Magnetic resonance in medicine 1989 Ronen S, Degani H